These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31248703)

  • 41. Antiretroviral therapy for prevention of HIV transmission: implications for Europe.
    Cambiano V; O'Connor J; Phillips AN; Rodger A; Lodwick R; Pharris A; Lampe F; Nakagawa F; Smith C; van de Laar MJ
    Euro Surveill; 2013 Nov; 18(48):20647. PubMed ID: 24308982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The HIV treatment cascade in acutely infected people: informing global guidelines.
    Rutstein SE; Sellers CJ; Ananworanich J; Cohen MS
    Curr Opin HIV AIDS; 2015 Nov; 10(6):395-402. PubMed ID: 26371460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dropout and re-enrollment: implications for epidemiological projections of treatment programs.
    Klein DJ; Bershteyn A; Eckhoff PA
    AIDS; 2014 Jan; 28 Suppl 1():S47-59. PubMed ID: 24468946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for HIV: systematic review to update the 2005 U.S. Preventive Services Task Force recommendation.
    Chou R; Selph S; Dana T; Bougatsos C; Zakher B; Blazina I; Korthuis PT
    Ann Intern Med; 2012 Nov; 157(10):706-18. PubMed ID: 23165662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons.
    Sabin CA; Cooper DA; Collins S; Schechter M
    AIDS; 2013 Jul; 27(12):1839-46. PubMed ID: 24179998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current status of HIV/AIDS in the ART era.
    Yoshimura K
    J Infect Chemother; 2017 Jan; 23(1):12-16. PubMed ID: 27825722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.
    Lahuerta M; Wu Y; Hoffman S; Elul B; Kulkarni SG; Remien RH; Nuwagaba-Biribonwoha H; El-Sadr W; Nash D; ;
    Clin Infect Dis; 2014 Feb; 58(3):432-41. PubMed ID: 24198226
    [TBL] [Abstract][Full Text] [Related]  

  • 49. WHO 'Treatment as Prevention' guidelines are unlikely to decrease HIV transmission in the UK unless undiagnosed HIV infections are reduced.
    Brown AE; Nardone A; Delpech VC
    AIDS; 2014 Jan; 28(2):281-3. PubMed ID: 24361685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
    Albert J; Berglund T; Gisslén M; Gröön P; Sönnerborg A; Tegnell A; Alexandersson A; Berggren I; Blaxhult A; Brytting M; Carlander C; Carlson J; Flamholc L; Follin P; Haggar A; Hansdotter F; Josephson F; Karlström O; Liljeros F; Navér L; Pettersson K; Johansson VS; Svennerholm B; Tunbäck P; Widgren K
    Scand J Infect Dis; 2014 Oct; 46(10):673-7. PubMed ID: 25073537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+).
    van Lettow M; Bedell R; Mayuni I; Mateyu G; Landes M; Chan AK; van Schoor V; Beyene T; Harries AD; Chu S; Mganga A; van Oosterhout JJ
    J Int AIDS Soc; 2014; 17(1):18994. PubMed ID: 25079437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral therapy for naïve and for treatment-experienced HIV patients, and prevention of HIV transmission.
    Antunes F
    Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S1-2. PubMed ID: 22156774
    [No Abstract]   [Full Text] [Related]  

  • 53. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
    Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
    Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV/AIDS.
    Saag MS; Masur H
    Infect Dis Clin North Am; 2014 Sep; 28(3):xv-xvi. PubMed ID: 25151570
    [No Abstract]   [Full Text] [Related]  

  • 56. Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.
    Hoffman RM; Leister E; Kacanek D; Shapiro DE; Read JS; Bryson Y; Currier JS
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):593-601. PubMed ID: 23714738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.
    Karris MY; Kao YT; Patel D; Dawson M; Woods SP; Vaida F; Spina C; Richman D; Little S; Smith DM
    AIDS; 2014 Mar; 28(6):841-9. PubMed ID: 24401640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.
    Cambiano V; Bertagnolio S; Jordan MR; Pillay D; Perriëns JH; Venter F; Lundgren J; Phillips A
    AIDS; 2014 Jan; 28 Suppl 1():S15-23. PubMed ID: 24468943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility.
    Ying R; Granich RM; Gupta S; Williams BG
    Clin Infect Dis; 2016 Apr; 62(8):1022-8. PubMed ID: 26826372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.